ReviewVaccines2024
Development of Vaccines against Emerging Mosquito-Vectored Arbovirus Infections.
Review in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- West Nile virus: epidemiology, prevention, clinical features, diagnosis, treatment, and open research questions.Annals of medicine · 2026Review
- Solanaceae-Derived Spirostane Saponins Inhibit Dengue Virus Replication and Viral Protein Expression and Exhibit Activity Against Multiple Arboviruses.Drug development research · 2026Article
- The ER-Resident Protein PDZD8 Inhibits Virus Production of West Nile Virus.Microbiology and immunology · 2026Article
- West Nile Neuroinvasive Disease: Current Management, Emerging Therapies and Future Clinical Trial Priorities.Reviews in medical virology · 2026Review
- In silico design of a multi-epitope vaccine targeting DENV-1 and DENV-3.Scientific reports · 2026Article
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- De-risking vaccine development: lessons, challenges, and prospects.NPJ vaccines · 2025Review
- Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.Virology journal · 2025Article
- The Influence of Heat on Pediatric and Perinatal Health: Risks, Evidence, and Future Directions.Journal of clinical medicine · 2025Review
- West Nile virus - a re-emerging global threat: recent advances in vaccines and drug discovery.Frontiers in cellular and infection microbiology · 2025Review
- Larvicidal and Oviposition Activity of Commercial Essential Oils ofMolecules (Basel, Switzerland) · 2024Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among emergent climate-sensitive infectious diseases, some mosquito-vectored arbovirus infections have epidemiological, social, and economic effects. Dengue virus (DENV), West Nile virus (WNV), and Chikungunya virus (CHIKV) disease, previously common only in the tropics, currently pose a major risk to global health and are expected to expand dramatically in the near future if adequate containment measures are not implemented. The lack of safe and effective vaccines is critical as it seems likely that emerging mosquito-vectored arbovirus infections will be con-trolled only when effective and safe vaccines against each of these infections become available. This paper discusses the clinical characteristics of DENV, WNV, and CHIKV infections and the state of development of vaccines against these viruses. An ideal vaccine should be able to evoke with a single administration a prompt activation of B and T cells, adequate concentrations of protecting/neutralizing antibodies, and the creation of a strong immune memory capable of triggering an effective secondary antibody response after new infection with a wild-type and/or mutated infectious agent. Moreover, the vaccine should be well tolerated, safe, easily administrated, cost-effective, and widely available throughout the world. However, the development of vaccines against emerging mosquito-vectored arbovirus diseases is far from being satisfactory, and it seems likely that it will take many years before effective and safe vaccines for all these infections are made available worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.